Antibody	Brand name	Approval date	Type	Target
Alemtuzumab	Campath	2001	humanized	CD52
Bevacizumab	Avastin	2004	humanized	vascular endothelial growth factor
Brentuximab vedotin	Adcetris	2011	chimeric	CD30
Cetuximab	Erbitux	2004	chimeric	epidermal growth factor receptor
Gemtuzumab ozogamicin	Mylotarg	2000	humanized	CD33
Ibritumomab tiuxetan	Zevalin	2002	murine	CD20
Panitumumab	Vectibix	2006	human	epidermal growth factor receptor
Rituximab	Rituxan, Mabthera	1997	chimeric	CD20
Trastuzumab	Herceptin	1998	humanized	ErbB2
